EyePoint Pharmaceuticals, Inc. — Director's Dealing 2018

Mar 21, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: pSivida Corp. (PSDV)
CIK: 0001314102
Period of Report: 2018-03-19

Reporting Person: Lurker Nancy (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-03-19	Common stock	A	38333	$0.00	Acquired	95033	Direct

Footnotes

F1: On March 19, 2018 (the "NDA Acceptance Date"), the U.S. Food and Drug Administration ("FDA") accepted pSivida Corp.'s (the "Company") new drug application for Durasert 3-year treatment for posterior segment uveitis. As a result, 19,166 shares representing a previously granted performance stock unit award vested on that date. An additional 19,167 shares from this award will vest on the first anniversary of the NDA Acceptance Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.